Form 4 Filing for AIM ImmunoTech Inc.

This filing reports a transaction by Thomas K Equels, CEO & President of AIM ImmunoTech Inc. On September 14, 2026, Mr. Equels acquired 5,900 shares of Common Stock at a price of $0.219 per share. This transaction was a purchase, indicated by the transaction code "P" and acquisition code "A". Following this transaction, Mr. Equels now owns 69,822 shares of the company's stock directly. The filing is made on Form 4, which is used to report changes in beneficial ownership of securities by insiders of public companies.